Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

Conditions

• Non-alcoholic Fatty Liver Disease

Interventions

• DRUG: LJN452

Sponsor

Novartis Pharmaceuticals